8-K
JOHNSON & JOHNSON (JNJ)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
October 19, 2021
Johnson & Johnson
(Exact name of registrant as specified in its charter)
| New Jersey | 1-3215 | 22-1024240 |
|---|---|---|
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number, including area code:
732-524-0400
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common Stock, Par Value $1.00 | JNJ | New York Stock Exchange |
| 0.250% Notes Due January 2022 | JNJ22 | New York Stock Exchange |
| 0.650% Notes Due May 2024 | JNJ24C | New York Stock Exchange |
| 5.50% Notes Due November 2024 | JNJ24BP | New York Stock Exchange |
| 1.150% Notes Due November 2028 | JNJ28 | New York Stock Exchange |
| 1.650% Notes Due May 2035 | JNJ35 | New York Stock Exchange |
Item 2.02 Results of Operations and Financial Condition
On October 19, 2021, Johnson & Johnson issued the attached press release announcing its sales and earnings for the third quarter ended October 3, 2021.
Item 7.01 Regulation FD Disclosure
Subsequent to the quarter, the Company’s wholly owned subsidiary LTL Management LLC (LTL), a newly created and separate subsidiary of Johnson & Johnson, that was established to hold and manage claims in the cosmetic talc litigation, has filed for voluntary Chapter 11 bankruptcy protection. This filing is intended to resolve all claims related to cosmetic talc in a manner that is equitable to all parties, including any current and future claimants. Johnson & Johnson and its other affiliates did not file for bankruptcy protection and will continue to operate their businesses as usual. To demonstrate its commitment to resolving the cosmetic talc cases and remove any financial objections to the process, Johnson & Johnson has agreed to provide funding to LTL for the payment of amounts the Bankruptcy Court determines are owed by LTL and will also establish a $2 billion trust in furtherance of this purpose. The $2 billion trust resulted in an incremental $1.4 billion litigation charge (recorded in Other income & expense) in the third fiscal quarter. While LTL pursues this equitable resolution, all pending cosmetic talc cases will be stayed. The press release further discussing this announcement is attached below as Exhibit 99.3.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
| Exhibit No. | Description of Exhibit |
|---|---|
| 99.1 | Press Release datedOctober19, 2021 for the period endedOctobera2021q3exhibit991.htm3, 2021 |
| 99.2 | Unaudited Comparative Supplementary Sales Data and Condensed Consolidated Statement of Earnings for thethirdquarter |
| 99.3 | Press Release dated October 14, 2021 |
| 104 | The cover page from this Current Report on Form 8-K, formatted in Inline XBRL. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Johnson & Johnson | |||
|---|---|---|---|
| (Registrant) | |||
| Date: | October 19, 2021 | By: | /s/ Robert J. Decker, Jr. |
| Robert J. Decker, Jr.<br>Controller<br>(Principal Accounting Officer) |
Document
Exhibit 99.1
JOHNSON & JOHNSON REPORTS 2021 THIRD-QUARTER RESULTS:
•Total sales growth of 10.7% to $23.3 Billion with operational growth of 9.9%* and adjusted operational growth of 10.6%*
•Earnings per share of $1.37 increasing 3.0% and adjusted earnings per share of $2.60 increasing 18.2%*
•Company increasing 2021 Full-Year Guidance
New Brunswick, N.J. (October 19, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2021. “Our third-quarter results demonstrate solid performance across Johnson & Johnson, driven by robust above-market results in Pharmaceuticals, ongoing recovery in Medical Devices, and strong growth in Consumer Health,” said Alex Gorsky, Chairman and Chief Executive Officer. “In the face of evolving marketplace dynamics resulting from the effects of COVID-19 and other global trends, we have continued to demonstrate the responsiveness and agility required to meet the needs of our stakeholders, while also successfully investing in a pipeline of innovation and key commercial platforms to drive our future growth. I am incredibly proud of our Company’s transformative growth over the last decade. As I prepare to transition the role of CEO to Joaquin Duato in January, I want to extend my deepest gratitude to our colleagues around the globe who work tirelessly to deliver solutions to address the world’s most urgent and unmet healthcare challenges.”
OVERALL FINANCIAL RESULTS:
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
4 Excludes intangible amortization expense and special items
REGIONAL SALES RESULTS:
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
Note: values may have been rounded
SEGMENT SALES RESULTS:
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
Note: values may have been rounded
Third Quarter 2021 SEGMENT COMMENTARY:
Consumer Health
Consumer Health worldwide operational sales, excluding the net impact of acquisitions and divestitures, increased 5.7%* primarily driven by over-the-counter (OTC) products. Major contributors to growth were TYLENOL and MOTRIN analgesics, upper respiratory products, and digestive health in OTC, and AVEENO in Skin Health / Beauty.
Pharmaceutical
Pharmaceutical worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 13.8%* driven by DARZALEX (daratumumab), for the treatment of multiple myeloma, STELARA (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases, TREMFYA (guselkumab), a biologic for the treatment of adults living with moderate to severe plaque psoriasis, and for adults with active psoriatic arthritis, ERLEADA (apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer, INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults, and OPSUMIT (macitentan) an oral endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension to delay disease progression. Also contributing to growth was sales of the not-for-profit COVID-19 Vaccine (Ad26.COV2.S) for the treatment of the SARS-CoV-2 virus. This growth was partially offset by declines in U.S. sales of REMICADE (infliximab), a biologic approved for the treatment of a number of immune-mediated inflammatory diseases, and INVOKANA (canagliflozin) for the treatment of adults with type 2 diabetes.
Medical Devices
Medical Devices worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 7.6%*, driven by electrophysiology products in Interventional Solutions, wound closure products in General Surgery, surgical vision products and contact lenses in Vision, trauma, hips, and knees in Orthopaedics, and energy, endocutters, and biosurgicals in Advanced Surgery. Growth was partially offset by Spine, Sports & Other.
NOTABLE NEW ANNOUNCEMENTS IN THE QUARTER:
The information contained in this section should be read in conjunction with Johnson & Johnson’s other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases available online in the Investors section of the Company’s website at news releases.
| Regulatory <br>Decisions | INVEGA HAFYERA (paliperidone palmitate) Receives FDA Approval For First and Only Twice-Yearly Treatment for Adults with Schizophrenia | (press release) | ||
|---|---|---|---|---|
| XARELTO (rivaroxaban) Plus Aspirin Receives FDA Approval For Expanded Peripheral Artery Disease (PAD) Indication to Include Patients After Lower-Extremity Revascularization (LER) | (press release) | |||
| UPTRAVI (selexipag) Receives FDA Approval For Intravenous Use in Adult Patients with Pulmonary Arterial Hypertension (PAH) | (press release) | |||
| Regulatory<br>Submissions | Johnson & Johnson Announces Submission of Emergency Use Authorization Amendment to the U.S. FDA to Support Booster of its Single-Shot COVID-19 Vaccine 1 | (press release) | ||
| Janssen Submits Application Seeking U.S. FDA Approval of STELARA (ustekinumab) for the Treatment of Pediatric Patients With Juvenile Psoriatic Arthritis 1 | (press release) | |||
| Other | Alex Gorsky to Transition Role of Chief Executive Officer of Johnson & Johnson to Joaquin Duato, Effective January 3, 2022 | (press release) | ||
| Dr. Paul Stoffels, Vice Chairman of the Executive Committee and Chief Scientific Officer of Johnson & Johnson to Retire, Effective December 31, 2021 1 | (press release) | |||
| Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Strong and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in the U.S. | (press release) | |||
| Johnson & Johnson Issues Statement on Nationwide Opioid Settlement Agreement | (press release) | |||
| DePuy Synthes Announces Introduction of the INHANCE Shoulder System, a First-to-Market, Fully Integrated Shoulder Arthroplasty System | (press release) | |||
| Janssen Announces Start of Phase 3 Trial for Investigational Respiratory Syncytial Virus (RSV) Vaccine in Older Adults | (press release) | |||
| Janssen Receives Positive CHMP Opinion for BYANNLI (six-monthly paliperidone palmitate) for the Maintenance Treatment of Schizophrenia in Adults | (press release) | |||
| Ethicon Announces ECHELON CIRCULAR Powered Stapler Associated with Major Reduction in Serious Complications Following Colorectal Surgery | (press release) | |||
| Johnson & Johnson Takes Steps to Equitably Resolve All Current and Future Talc Claims 1 | (press release) | |||
| Janssen Receives Positive CHMP Opinion for RYBREVANT (amivantamab) for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations After Failure of Platinum-Based Therapy 1 | (press release) | |||
| Johnson & Johnson COVID-19 Vaccine Booster Shot Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee 1 | (press release) |
1 Subsequent to the quarter
FULL-YEAR 2021 GUIDANCE:
Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.
| ($ in Billions, except EPS) | October 2021<br> (Base Business) | October 2021(incl. COVID Vx) | July 2021 <br>(incl. COVID Vx) |
|---|---|---|---|
| Adjusted Operational Sales1,2<br><br>Change vs. Prior Year | 9.9% - 10.5% | 12.9% - 13.5% | 12.5% - 13.5% |
| Operational Sales2<br><br>Change vs. Prior Year | $90.3B – 90.8B<br>9.4% – 10.0% | 92.8 - 93.3B12.4% – 13.0% | $92.5B - $93.3B<br>12.0% – 13.0% |
| Estimated Reported Sales3<br><br>Change vs. Prior Year | $91.6B - $92.1B<br>10.9% – 11.5% | 94.1B - 94.6B13.9% – 14.5% | $93.8B - $94.6B<br>13.5% – 14.5% |
| Adjusted Operational EPS (Diluted)2,4<br><br>Change vs. Prior Year | 9.65 - 9.7020.2% - 20.8% | $9.50 - $9.60<br> 18.4% - 19.6% | |
| Adjusted EPS (Diluted)3,4<br><br>Change vs. Prior Year | 9.77 - 9.8221.7% - 22.3% | $9.60 - $9.70<br> 19.6% - 20.8% |
All values are in US Dollars.
1 Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures
2 Non-GAAP financial measure; excludes the impact of translational currency
3 Calculated using Euro Average Rate: July 2021 = $1.19 and October = $1.19 (Illustrative purposes only)
4 Non-GAAP financial measure; excludes intangible amortization expense and special items
Note: % may have been rounded
Other modeling considerations will be provided on the webcast.
WEBCAST INFORMATION:
Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the live webcast in the Investors section of the Company's website at events-and-presentations.
ABOUT JOHNSON & JOHNSON:
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a
healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.
NON-GAAP FINANCIAL MEASURES:
*Operational sales growth excluding the impact of translational currency, adjusted operational sales growth excluding the net impact of acquisitions and divestitures and translational currency, as well as adjusted net earnings, adjusted diluted earnings per share and adjusted operational diluted earnings per share excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investors section of the company's website at quarterly-results.
Copies of the financial schedules accompanying this earnings release are available on the Company’s website at quarterly-results. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, a pharmaceutical pipeline of selected compounds in late stage development and a copy of today’s earnings call presentation can also be found in the Investors section of the Company's website at quarterly-results.
NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS:
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays and cancellations of medical procedures, supply chain disruptions and other impacts to the business, or on the Company’s ability to execute business continuity plans, as a result of the COVID-19 pandemic, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2021 including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” in the Company’s most recently filed Quarterly Report on Form 10-Q and the Company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
| Press Contacts: | Investor Contacts: | ||
|---|---|---|---|
| Courtney Dugan | Jennifer McIntyre | Sarah Wood | Lisa Romanko |
| (347) 452-1061 | (732) 524-3922 | (732) 524-2617 | (732) 524-2034 |
Document
Exhibit 99.2
| Johnson & Johnson and Subsidiaries | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Supplementary Sales Data | |||||||||
| (Unaudited; Dollars in Millions) | THIRD QUARTER | ||||||||
| Percent Change | |||||||||
| 2021 | 2020 | Total | Operations | Currency | |||||
| Sales to customers by | |||||||||
| geographic area | |||||||||
| U.S. | $ | 11,963 | 11,086 | 7.9 | % | 7.9 | — | ||
| Europe | 5,587 | 4,819 | 15.9 | 14.6 | 1.3 | ||||
| Western Hemisphere excluding U.S. | 1,500 | 1,296 | 15.7 | 13.4 | 2.3 | ||||
| Asia-Pacific, Africa | 4,288 | 3,881 | 10.5 | 8.5 | 2.0 | ||||
| International | 11,375 | 9,996 | 13.8 | 12.1 | 1.7 | ||||
| Worldwide | $ | 23,338 | 21,082 | 10.7 | % | 9.9 | 0.8 | ||
| Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. | |||||||||
| Johnson & Johnson and Subsidiaries | |||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | ||
| Supplementary Sales Data | |||||||||
| (Unaudited; Dollars in Millions) | NINE MONTHS | ||||||||
| Percent Change | |||||||||
| 2021 | 2020 | Total | Operations | Currency | |||||
| Sales to customers by | |||||||||
| geographic area | |||||||||
| U.S. | $ | 34,993 | 31,324 | 11.7 | % | 11.7 | — | ||
| Europe | 16,669 | 13,709 | 21.6 | 15.3 | 6.3 | ||||
| Western Hemisphere excluding U.S. | 4,291 | 3,931 | 9.2 | 8.1 | 1.1 | ||||
| Asia-Pacific, Africa | 13,018 | 11,145 | 16.8 | 12.3 | 4.5 | ||||
| International | 33,978 | 28,785 | 18.0 | 13.1 | 4.9 | ||||
| Worldwide | $ | 68,971 | 60,109 | 14.7 | % | 12.4 | 2.3 | ||
| Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. | |||||||||
| Johnson & Johnson and Subsidiaries | |||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | ||
| Supplementary Sales Data | |||||||||
| (Unaudited; Dollars in Millions) | THIRD QUARTER | ||||||||
| Percent Change | |||||||||
| 2021 | 2020 | Total | Operations | Currency | |||||
| Sales to customers by | |||||||||
| segment of business | |||||||||
| Consumer Health | |||||||||
| U.S. | $ | 1,625 | 1,556 | 4.5 | % | 4.5 | — | ||
| International | 2,075 | 1,958 | 5.9 | 3.7 | 2.2 | ||||
| 3,700 | 3,514 | 5.3 | 4.1 | 1.2 | |||||
| Pharmaceutical | |||||||||
| U.S. | 7,221 | 6,438 | 12.2 | 12.2 | — | ||||
| International | 5,773 | 4,980 | 15.9 | 14.6 | 1.3 | ||||
| 12,994 | 11,418 | 13.8 | 13.2 | 0.6 | |||||
| Medical Devices | |||||||||
| U.S. | 3,117 | 3,092 | 0.8 | 0.8 | — | ||||
| International | 3,527 | 3,058 | 15.4 | 13.3 | 2.1 | ||||
| 6,644 | 6,150 | 8.0 | 7.0 | 1.0 | |||||
| U.S. | 11,963 | 11,086 | 7.9 | 7.9 | — | ||||
| International | 11,375 | 9,996 | 13.8 | 12.1 | 1.7 | ||||
| Worldwide | $ | 23,338 | 21,082 | 10.7 | % | 9.9 | 0.8 | ||
| Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. | |||||||||
| Johnson & Johnson and Subsidiaries | |||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | ||
| Supplementary Sales Data | |||||||||
| (Unaudited; Dollars in Millions) | NINE MONTHS | ||||||||
| Percent Change | |||||||||
| 2021 | 2020 | Total | Operations | Currency | |||||
| Sales to customers by | |||||||||
| segment of business | |||||||||
| Consumer Health | |||||||||
| U.S. | $ | 4,987 | 4,853 | 2.8 | % | 2.8 | — | ||
| International | 5,991 | 5,582 | 7.3 | 3.5 | 3.8 | ||||
| 10,978 | 10,435 | 5.2 | 3.1 | 2.1 | |||||
| Pharmaceutical | |||||||||
| U.S. | 20,536 | 18,619 | 10.3 | 10.3 | — | ||||
| International | 17,256 | 14,685 | 17.5 | 12.5 | 5.0 | ||||
| 37,792 | 33,304 | 13.5 | 11.3 | 2.2 | |||||
| Medical Devices | |||||||||
| U.S. | 9,470 | 7,852 | 20.6 | 20.6 | — | ||||
| International | 10,731 | 8,518 | 26.0 | 20.5 | 5.5 | ||||
| 20,201 | 16,370 | 23.4 | 20.5 | 2.9 | |||||
| U.S. | 34,993 | 31,324 | 11.7 | 11.7 | — | ||||
| International | 33,978 | 28,785 | 18.0 | 13.1 | 4.9 | ||||
| Worldwide | $ | 68,971 | 60,109 | 14.7 | % | 12.4 | 2.3 | ||
| Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. | |||||||||
| Johnson & Johnson and Subsidiaries | |||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Condensed Consolidated Statement of Earnings | |||||||||
| (Unaudited; in Millions Except Per Share Figures) | THIRD QUARTER | ||||||||
| 2021 | 2020 | Percent | |||||||
| Percent | Percent | Increase | |||||||
| Amount | to Sales | Amount | to Sales | (Decrease) | |||||
| Sales to customers | $ | 23,338 | 100.0 | $ | 21,082 | 100.0 | 10.7 | ||
| Cost of products sold | 7,250 | 31.1 | 6,972 | 33.1 | 4.0 | ||||
| Gross Profit | 16,088 | 68.9 | 14,110 | 66.9 | 14.0 | ||||
| Selling, marketing and administrative expenses | 6,000 | 25.7 | 5,431 | 25.8 | 10.5 | ||||
| Research and development expense | 3,422 | 14.7 | 2,840 | 13.5 | 20.5 | ||||
| In-process research and development | 900 | 3.9 | 138 | 0.6 | |||||
| Interest (income) expense, net | 7 | 0.0 | 32 | 0.1 | |||||
| Other (income) expense, net | 1,850 | 7.9 | 1,200 | 5.7 | |||||
| Restructuring | 60 | 0.2 | 68 | 0.3 | |||||
| Earnings before provision for taxes on income | 3,849 | 16.5 | 4,401 | 20.9 | (12.5) | ||||
| Provision for taxes on income | 182 | 0.8 | 847 | 4 | (78.5) | ||||
| Net earnings | $ | 3,667 | 15.7 | $ | 3,554 | 16.9 | 3.2 | ||
| Net earnings per share (Diluted) | $ | 1.37 | $ | 1.33 | 3.0 | ||||
| Average shares outstanding (Diluted) | 2,674.9 | 2,669.3 | |||||||
| Effective tax rate | 4.7 | % | 19.2 | % | |||||
| Adjusted earnings before provision for taxes and net earnings (1) (A) | |||||||||
| Earnings before provision for taxes on income | $ | 8,058 | 34.5 | $ | 7,246 | 34.4 | 11.2 | ||
| Net earnings | $ | 6,968 | 29.9 | $ | 5,868 | 27.8 | 18.7 | ||
| Net earnings per share (Diluted) | $ | 2.60 | $ | 2.20 | 18.2 | ||||
| Effective tax rate | 13.5 | % | 19.0 | % | |||||
| (1) See Reconciliation of Non-GAAP Financial Measures. | |||||||||
| (A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant gains from divestitures, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. | |||||||||
| Johnson & Johnson and Subsidiaries | |||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Condensed Consolidated Statement of Earnings | |||||||||
| (Unaudited; in Millions Except Per Share Figures) | NINE MONTHS | ||||||||
| 2021 | 2020 | Percent | |||||||
| Percent | Percent | Increase | |||||||
| Amount | to Sales | Amount | to Sales | (Decrease) | |||||
| Sales to customers | $ | 68,971 | 100.0 | $ | 60,109 | 100.0 | 14.7 | ||
| Cost of products sold | 21,900 | 31.8 | 20,613 | 34.3 | 6.2 | ||||
| Gross Profit | 47,071 | 68.2 | 39,496 | 65.7 | 19.2 | ||||
| Selling, marketing and administrative expenses | 17,505 | 25.4 | 15,627 | 26.0 | 12.0 | ||||
| Research and development expense | 9,994 | 14.5 | 8,127 | 13.5 | 23.0 | ||||
| In-process research and development | 900 | 1.3 | 144 | 0.3 | |||||
| Interest (income) expense, net | 83 | 0.1 | 16 | 0.0 | |||||
| Other (income) expense, net | 480 | 0.7 | 545 | 0.9 | |||||
| Restructuring | 169 | 0.2 | 187 | 0.3 | |||||
| Earnings before provision for taxes on income | 17,940 | 26.0 | 14,850 | 24.7 | 20.8 | ||||
| Provision for taxes on income | 1,798 | 2.6 | 1,874 | 3.1 | (4.1) | ||||
| Net earnings | $ | 16,142 | 23.4 | $ | 12,976 | 21.6 | 24.4 | ||
| Net earnings per share (Diluted) | $ | 6.04 | $ | 4.86 | 24.3 | ||||
| Average shares outstanding (Diluted) | 2,674.6 | 2,670.8 | |||||||
| Effective tax rate | 10.0 | % | 12.6 | % | |||||
| Adjusted earnings before provision for taxes and net earnings (1) (A) | |||||||||
| Earnings before provision for taxes on income | $ | 24,125 | 35.0 | $ | 19,827 | 33.0 | 21.7 | ||
| Net earnings | $ | 20,517 | 29.7 | $ | 16,468 | 27.4 | 24.6 | ||
| Net earnings per share (Diluted) | $ | 7.67 | $ | 6.17 | 24.3 | ||||
| Effective tax rate | 15.0 | % | 16.9 | % | |||||
| (1) See Reconciliation of Non-GAAP Financial Measures. | |||||||||
| (A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant gains from divestitures, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. | |||||||||
| Johnson & Johnson and Subsidiaries | |||||||||
| --- | --- | --- | |||||||
| Reconciliation of Non-GAAP Financial Measures | |||||||||
| Third Quarter | |||||||||
| (Dollars in Millions Except Per Share Data) | 2021 | ||||||||
| Net Earnings, after tax- as reported | 3,667 | ||||||||
| Pre-tax Adjustments | |||||||||
| Intangible Asset Amortization expense | 1,159 | ||||||||
| Litigation expense, net | 2,077 | ||||||||
| IPR&D | 900 | ||||||||
| Restructuring related | 121 | ||||||||
| Acquisition, integration and divestiture related | 20 | ||||||||
| (Gains)/losses on securities | (127) | ||||||||
| Medical Device Regulation | 59 | ||||||||
| Other | - | ||||||||
| Tax Adjustments | |||||||||
| Tax impact on special item adjustments 1 | (849) | ||||||||
| Tax legislation and related impacts | (59) | ||||||||
| Adjusted Net Earnings, after tax | 6,968 | ||||||||
| Average shares outstanding (Diluted) | 2,674.9 | ||||||||
| Adjusted net earnings per share (Diluted) | 2.60 | ||||||||
| Operational adjusted net earnings per share (Diluted) | 2.56 | ||||||||
| Notes: | |||||||||
| 1 | The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings. |
All values are in US Dollars.
| Johnson & Johnson and Subsidiaries | |
|---|---|
| Reconciliation of Non-GAAP Financial Measures | |
| (Dollars in Millions Except Per Share Data) | |
| Net Earnings, after tax- as reported | |
| Pre-tax Adjustments | |
| Intangible Asset Amortization expense | |
| Litigation expense, net | |
| IPR&D | |
| Restructuring related | |
| Acquisition, integration and divestiture related 1 | |
| (Gains)/losses on securities | |
| Medical Device Regulation | |
| Other | |
| Tax Adjustments | |
| Tax impact on special item adjustments 2 | |
| Tax legislation and related impacts | |
| Adjusted Net Earnings, after tax | |
| Average shares outstanding (Diluted) | |
| Adjusted net earnings per share (Diluted) | |
| Operational adjusted net earnings per share (Diluted) | |
| Notes: | |
| 1 | Acquisition, integration and divestiture related for the nine months of 2021 primarily includes the gain on the divestiture of two Pharmaceutical brands outside of the U.S. Acquisition, integration and divestiture related for 2020 primarily includes a Contingent Consideration reversal (165M in third quarter and 1,148M in nine months) related to the timing of certain developmental milestones associated with the Auris Health acquisition. |
| 2 | The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings. |
All values are in US Dollars.
| Johnson & Johnson and Subsidiaries | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Reconciliation of Non-GAAP Financial Measure | |||||||||
| Adjusted Operational Sales Growth (A) | |||||||||
| THIRD QUARTER 2021 ACTUAL vs. 2020 ACTUAL | |||||||||
| Segments | |||||||||
| Consumer Health | Pharmaceutical | Medical Devices | Total | ||||||
| WW As Reported | 5.3 | % | 13.8 | % | 8.0 | % | 10.7 | % | |
| U.S. | 4.5 | % | 12.2 | % | 0.8 | % | 7.9 | % | |
| International | 5.9 | % | 15.9 | % | 15.4 | % | 13.8 | % | |
| WW Currency | 1.2 | 0.6 | 1.0 | 0.8 | |||||
| U.S. | — | — | — | — | |||||
| International | 2.2 | 1.3 | 2.1 | 1.7 | |||||
| WW Operational | 4.1 | % | 13.2 | % | 7.0 | % | 9.9 | % | |
| U.S. | 4.5 | % | 12.2 | % | 0.8 | % | 7.9 | % | |
| International | 3.7 | % | 14.6 | % | 13.3 | % | 12.1 | % | |
| General Surgery | |||||||||
| Advanced Sterilization Products | 0.4 | 0.1 | |||||||
| U.S. | 0.0 | 0.0 | |||||||
| International | 0.8 | 0.2 | |||||||
| Skin Health / Beauty | |||||||||
| Dr. Ci Labo - Sedona | 1.1 | 0.2 | |||||||
| U.S. | 0.0 | 0.0 | |||||||
| International | 2.0 | 0.4 | |||||||
| All Other Acquisitions and Divestitures | 0.5 | 0.6 | 0.2 | 0.4 | |||||
| U.S. | 0.6 | 0.0 | 0.3 | 0.1 | |||||
| International | 0.3 | 1.4 | 0.0 | 0.8 | |||||
| WW Adjusted Operational | 5.7 | % | 13.8 | % | 7.6 | % | 10.6 | % | |
| U.S. | 5.1 | % | 12.2 | % | 1.1 | % | 8.0 | % | |
| International | 6.1 | % | 16.0 | % | 14.1 | % | 13.5 | % | |
| Note: Percentages are based on actual, non-rounded figures and may not sum | |||||||||
| (A) NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry. | |||||||||
| Johnson & Johnson and Subsidiaries | |||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | |
| Reconciliation of Non-GAAP Financial Measure | |||||||||
| Adjusted Operational Sales Growth (A) | |||||||||
| NINE MONTHS 2021 ACTUAL vs. 2020 ACTUAL | |||||||||
| Segments | |||||||||
| Consumer Health | Pharmaceutical | Medical Devices | Total | ||||||
| WW As Reported | 5.2 | % | 13.5 | % | 23.4 | % | 14.7 | % | |
| U.S. | 2.8 | % | 10.3 | % | 20.6 | % | 11.7 | % | |
| International | 7.3 | % | 17.5 | % | 26.0 | % | 18.0 | % | |
| WW Currency | 2.1 | 2.2 | 2.9 | 2.3 | |||||
| U.S. | — | — | — | — | |||||
| International | 3.8 | 5.0 | 5.5 | 4.9 | |||||
| WW Operational | 3.1 | % | 11.3 | % | 20.5 | % | 12.4 | % | |
| U.S. | 2.8 | % | 10.3 | % | 20.6 | % | 11.7 | % | |
| International | 3.5 | % | 12.5 | % | 20.5 | % | 13.1 | % | |
| General Surgery | |||||||||
| Advanced Sterilization Products | 0.6 | 0.2 | |||||||
| U.S. | 0.0 | 0.0 | |||||||
| International | 1.2 | 0.3 | |||||||
| Skin Health / Beauty | |||||||||
| Dr. Ci Labo - Sedona | 0.5 | 0.1 | |||||||
| U.S. | 0.0 | 0.0 | |||||||
| International | 0.9 | 0.2 | |||||||
| All Other Acquisitions and Divestitures | 0.5 | 0.5 | 0.2 | 0.4 | |||||
| U.S. | 0.5 | (0.1) | 0.4 | 0.1 | |||||
| International | 0.3 | 1.3 | 0.0 | 0.7 | |||||
| WW Adjusted Operational | 4.1 | % | 11.8 | % | 21.4 | % | 13.1 | % | |
| U.S. | 3.3 | % | 10.2 | % | 21.0 | % | 11.8 | % | |
| International | 4.7 | % | 13.8 | % | 21.7 | % | 14.4 | % | |
| Note: Percentages are based on actual, non-rounded figures and may not sum | |||||||||
| (A) NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry. | |||||||||
| Johnson & Johnson | |||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Segment Sales | |||||||||
| (Dollars in Millions) | |||||||||
| THIRD QUARTER | |||||||||
| % Change | |||||||||
| 2021 | 2020 | Reported | Operational (1) | Currency | |||||
| CONSUMER HEALTH SEGMENT (2) | |||||||||
| OTC | |||||||||
| US | $ | 686 | 601 | 14.0 | % | 14.0 | % | — | % |
| Intl | 686 | 541 | 26.9 | 22.8 | 4.1 | ||||
| WW | 1,372 | 1,142 | 20.1 | 18.2 | 1.9 | ||||
| SKIN HEALTH / BEAUTY | |||||||||
| US | 569 | 572 | (0.5) | (0.5) | — | ||||
| Intl | 555 | 577 | (3.8) | (5.5) | 1.7 | ||||
| WW | 1,124 | 1,149 | (2.2) | (3.0) | 0.8 | ||||
| ORAL CARE | |||||||||
| US | 150 | 164 | (8.4) | (8.4) | — | ||||
| Intl | 248 | 248 | 0.1 | (1.8) | 1.9 | ||||
| WW | 398 | 412 | (3.3) | (4.5) | 1.2 | ||||
| BABY CARE | |||||||||
| US | 95 | 91 | 5.2 | 5.2 | — | ||||
| Intl | 296 | 302 | (2.0) | (3.1) | 1.1 | ||||
| WW | 391 | 393 | (0.3) | (1.2) | 0.9 | ||||
| WOMEN'S HEALTH | |||||||||
| US | 3 | 3 | 20.1 | 20.1 | — | ||||
| Intl | 229 | 227 | 0.5 | 0.6 | (0.1) | ||||
| WW | 232 | 230 | 0.8 | 0.8 | 0.0 | ||||
| WOUND CARE / OTHER | |||||||||
| US | 122 | 125 | (2.6) | (2.6) | — | ||||
| Intl | 61 | 64 | (5.2) | (9.0) | 3.8 | ||||
| WW | 182 | 189 | (3.5) | (4.8) | 1.3 | ||||
| TOTAL CONSUMER HEALTH | |||||||||
| US | 1,625 | 1,556 | 4.5 | 4.5 | — | ||||
| Intl | 2,075 | 1,958 | 5.9 | 3.7 | 2.2 | ||||
| WW | $ | 3,700 | 3,514 | 5.3 | % | 4.1 | % | 1.2 | % |
| See footnotes at end of schedule | |||||||||
| Johnson & Johnson | |||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Segment Sales | |||||||||
| (Dollars in Millions) | |||||||||
| THIRD QUARTER | |||||||||
| % Change | |||||||||
| 2021 | 2020 | Reported | Operational (1) | Currency | |||||
| PHARMACEUTICAL SEGMENT (2) (3) | |||||||||
| IMMUNOLOGY | |||||||||
| US | $ | 2,771 | 2,558 | 8.3 | % | 8.3 | % | — | % |
| Intl | 1,480 | 1,230 | 20.3 | 18.8 | 1.5 | ||||
| WW | 4,250 | 3,789 | 12.2 | 11.7 | 0.5 | ||||
| REMICADE | |||||||||
| US | 480 | 634 | (24.3) | (24.3) | — | ||||
| US Exports (4) | 47 | 78 | (40.2) | (40.2) | — | ||||
| Intl | 234 | 209 | 12.2 | 8.1 | 4.1 | ||||
| WW | 761 | 921 | (17.4) | (18.3) | 0.9 | ||||
| SIMPONI / SIMPONI ARIA | |||||||||
| US | 295 | 312 | (5.3) | (5.3) | — | ||||
| Intl | 276 | 280 | (1.1) | (0.7) | (0.4) | ||||
| WW | 571 | 592 | (3.3) | (3.1) | (0.2) | ||||
| STELARA | |||||||||
| US | 1,569 | 1,313 | 19.5 | 19.5 | — | ||||
| Intl | 809 | 634 | 27.7 | 26.3 | 1.4 | ||||
| WW | 2,378 | 1,947 | 22.2 | 21.7 | 0.5 | ||||
| TREMFYA | |||||||||
| US | 376 | 222 | 69.7 | 69.7 | — | ||||
| Intl | 161 | 105 | 52.5 | 50.5 | 2.0 | ||||
| WW | 537 | 327 | 64.1 | 63.5 | 0.6 | ||||
| OTHER IMMUNOLOGY | |||||||||
| US | 3 | — | * | * | — | ||||
| Intl | 0 | 3 | * | * | * | ||||
| WW | 3 | 3 | (26.4) | (27.5) | 1.1 | ||||
| INFECTIOUS DISEASES | |||||||||
| US | 679 | 413 | 64.3 | 64.3 | — | ||||
| Intl | 709 | 451 | 57.2 | 55.6 | 1.6 | ||||
| WW | 1,389 | 864 | 60.6 | 59.8 | 0.8 | ||||
| COVID-19 VACCINE | |||||||||
| US | 270 | — | * | * | — | ||||
| Intl | 233 | — | * | * | — | ||||
| WW | 502 | — | * | * | — | ||||
| EDURANT / rilpivirine | |||||||||
| US | 12 | 11 | 8.4 | 8.4 | — | ||||
| Intl | 247 | 226 | 9.7 | 8.7 | 1.0 | ||||
| WW | 259 | 236 | 9.6 | 8.6 | 1.0 | ||||
| PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | |||||||||
| US | 380 | 379 | 0.4 | 0.4 | — | ||||
| Intl | 137 | 147 | (7.1) | (8.8) | 1.7 | ||||
| WW | 517 | 526 | (1.7) | (2.2) | 0.5 | ||||
| OTHER INFECTIOUS DISEASES | |||||||||
| US | 18 | 24 | (26.0) | (26.0) | — | ||||
| Intl | 93 | 78 | 18.3 | 15.2 | 3.1 | ||||
| WW | 110 | 102 | 7.8 | 5.4 | 2.4 | ||||
| See footnotes at end of schedule | |||||||||
| Johnson & Johnson | |||||||||
| --- | --- | --- | --- | --- | --- | --- | |||
| Segment Sales | |||||||||
| (Dollars in Millions) | |||||||||
| THIRD QUARTER | |||||||||
| % Change | |||||||||
| 2021 | 2020 | Reported | Operational (1) | Currency | |||||
| PHARMACEUTICAL SEGMENT (2) (3) (Continued) | |||||||||
| NOSCIENCE | |||||||||
| US | 835 | 759 | 10.2 | % | 10.2% | —% | |||
| Intl | 854 | 846 | 0.8 | (0.5) | 1.3 | ||||
| WW | 1,689 | 1,605 | 5.3 | 4.6 | 0.7 | ||||
| CONCERTA / methylphenidate | |||||||||
| US | 35 | 43 | (19.5) | (19.5) | — | ||||
| Intl | 122 | 107 | 14.2 | 12.5 | 1.7 | ||||
| WW | 157 | 149 | 4.5 | 3.3 | 1.2 | ||||
| INVEGA SUSTENNA / XEPLION / INVEGA | |||||||||
| TRINZA / TREVICTA | |||||||||
| US | 648 | 585 | 11.0 | 11.0 | — | ||||
| Intl | 355 | 341 | 4.3 | 3.2 | 1.1 | ||||
| WW | 1,004 | 926 | 8.5 | 8.1 | 0.4 | ||||
| RISPERDAL CONSTA | |||||||||
| US | 71 | 70 | 1.3 | 1.3 | — | ||||
| Intl | 69 | 81 | (16.7) | (16.0) | (0.7) | ||||
| WW | 140 | 152 | (8.4) | (8.0) | (0.4) | ||||
| OTHER NOSCIENCE | |||||||||
| US | 81 | 60 | 34.7 | 34.7 | — | ||||
| Intl | 307 | 317 | (2.9) | (4.8) | 1.9 | ||||
| WW | 388 | 377 | 3.1 | 1.5 | 1.6 | ||||
| ONCOLOGY | |||||||||
| US | 1,525 | 1,267 | 20.3 | 20.3 | — | ||||
| Intl | 2,140 | 1,862 | 14.9 | 13.8 | 1.1 | ||||
| WW | 3,665 | 3,129 | 17.1 | 16.5 | 0.6 | ||||
| DARZALEX | |||||||||
| US | 841 | 585 | 43.7 | 43.7 | — | ||||
| Intl | 739 | 514 | 43.7 | 42.0 | 1.7 | ||||
| WW | 1,580 | 1,099 | 43.7 | 42.9 | 0.8 | ||||
| ERLEADA | |||||||||
| US | 214 | 152 | 40.5 | 40.5 | — | ||||
| Intl | 130 | 55 | * | * | * | ||||
| WW | 344 | 206 | 66.7 | 65.8 | 0.9 | ||||
| IMBRUVICA | |||||||||
| US | 413 | 450 | (8.3) | (8.3) | — | ||||
| Intl | 654 | 581 | 12.6 | 10.9 | 1.7 | ||||
| WW | 1,066 | 1,031 | 3.5 | 2.5 | 1.0 | ||||
| ZYTIGA / abiraterone acetate | |||||||||
| US | 25 | 58 | (57.0) | (57.0) | — | ||||
| Intl | 523 | 532 | (1.8) | (2.1) | 0.3 | ||||
| WW | 548 | 590 | (7.2) | (7.5) | 0.3 | ||||
| OTHER ONCOLOGY | |||||||||
| US | 32 | 21 | 49.6 | 49.6 | — | ||||
| Intl | 94 | 181 | (48.0) | (47.2) | (0.8) | ||||
| WW | 126 | 203 | (37.6) | (36.9) | (0.7) | ||||
| See footnotes at end of schedule |
All values are in Euros.
| Johnson & Johnson | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Segment Sales | |||||||||
| (Dollars in Millions) | |||||||||
| THIRD QUARTER | |||||||||
| % Change | |||||||||
| 2021 | 2020 | Reported | Operational (1) | Currency | |||||
| PHARMACEUTICAL SEGMENT (2) (3) (Continued) | |||||||||
| PULMONARY HYPERTENSION | |||||||||
| US | $ | 610 | 510 | 19.7 | % | 19.7 | % | — | % |
| Intl | 258 | 239 | 7.9 | 8.4 | (0.5) | ||||
| WW | 868 | 749 | 15.9 | 16.1 | (0.2) | ||||
| OPSUMIT | |||||||||
| US | 299 | 244 | 22.8 | 22.8 | — | ||||
| Intl | 159 | 148 | 7.4 | 7.8 | (0.4) | ||||
| WW | 458 | 392 | 17.0 | 17.1 | (0.1) | ||||
| UPTRAVI | |||||||||
| US | 265 | 226 | 17.3 | 17.3 | — | ||||
| Intl | 44 | 34 | 30.4 | 28.8 | 1.6 | ||||
| WW | 309 | 260 | 19.0 | 18.8 | 0.2 | ||||
| OTHER PULMONARY HYPERTENSION | |||||||||
| US | 47 | 40 | 14.4 | 14.4 | — | ||||
| Intl | 54 | 57 | (4.4) | (2.1) | (2.3) | ||||
| WW | 101 | 97 | 3.4 | 4.8 | (1.4) | ||||
| CARDIOVASCULAR / METABOLISM / OTHER | |||||||||
| US | 800 | 931 | (14.0) | (14.0) | — | ||||
| Intl | 333 | 351 | (5.1) | (8.2) | 3.1 | ||||
| WW | 1,133 | 1,281 | (11.5) | (12.4) | 0.9 | ||||
| XARELTO | |||||||||
| US | 636 | 630 | 0.8 | 0.8 | — | ||||
| Intl | — | — | — | — | — | ||||
| WW | 636 | 630 | 0.8 | 0.8 | — | ||||
| INVOKANA / INVOKAMET | |||||||||
| US | 66 | 156 | (57.4) | (57.4) | — | ||||
| Intl | 67 | 68 | (1.0) | (4.3) | 3.3 | ||||
| WW | 133 | 224 | (40.3) | (41.3) | 1.0 | ||||
| PROCRIT / EPREX | |||||||||
| US | 47 | 69 | (30.9) | (30.9) | — | ||||
| Intl | 65 | 63 | 3.1 | 0.5 | 2.6 | ||||
| WW | 112 | 132 | (14.6) | (15.8) | 1.2 | ||||
| OTHER | |||||||||
| US | 51 | 75 | (32.6) | (32.6) | — | ||||
| Intl | 200 | 219 | (8.7) | (11.9) | 3.2 | ||||
| WW | 251 | 294 | (14.8) | (17.2) | 2.4 | ||||
| TOTAL PHARMACEUTICAL | |||||||||
| US | 7,221 | 6,438 | 12.2 | 12.2 | — | ||||
| Intl | 5,773 | 4,980 | 15.9 | 14.6 | 1.3 | ||||
| WW | $ | 12,994 | 11,418 | 13.8 | % | 13.2 | % | 0.6 | % |
| See footnotes at end of schedule | |||||||||
| Johnson & Johnson | |||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Segment Sales | |||||||||
| (Dollars in Millions) | |||||||||
| THIRD QUARTER | |||||||||
| % Change | |||||||||
| 2021 | 2020 | Reported | Operational (1) | Currency | |||||
| MEDICAL DEVICES SEGMENT (2) | |||||||||
| INTERVENTIONAL SOLUTIONS | |||||||||
| US | $ | 444 | 399 | 11.1 | % | 11.1 | % | — | % |
| Intl | 513 | 437 | 17.7 | 15.1 | 2.6 | ||||
| WW | 957 | 836 | 14.5 | 13.2 | 1.3 | ||||
| ORTHOPAEDICS | |||||||||
| US | 1,249 | 1,308 | (4.5) | (4.5) | — | ||||
| Intl | 843 | 774 | 8.8 | 6.8 | 2.0 | ||||
| WW | 2,093 | 2,083 | 0.5 | (0.3) | 0.8 | ||||
| HIPS | |||||||||
| US | 210 | 221 | (5.3) | (5.3) | — | ||||
| Intl | 146 | 124 | 18.8 | 16.0 | 2.8 | ||||
| WW | 356 | 345 | 3.3 | 2.3 | 1.0 | ||||
| KNEES | |||||||||
| US | 184 | 205 | (9.8) | (9.8) | — | ||||
| Intl | 131 | 102 | 28.1 | 25.9 | 2.2 | ||||
| WW | 316 | 308 | 2.8 | 2.1 | 0.7 | ||||
| TRAUMA | |||||||||
| US | 455 | 433 | 5.3 | 5.3 | — | ||||
| Intl | 260 | 253 | 2.4 | 0.9 | 1.5 | ||||
| WW | 715 | 685 | 4.2 | 3.7 | 0.5 | ||||
| SPINE, SPORTS & OTHER | |||||||||
| US | 400 | 449 | (11.1) | (11.1) | — | ||||
| Intl | 306 | 295 | 3.5 | 1.5 | 2.0 | ||||
| WW | 705 | 745 | (5.3) | (6.1) | 0.8 | ||||
| See footnotes at end of schedule | |||||||||
| Johnson & Johnson | |||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Segment Sales | |||||||||
| (Dollars in Millions) | |||||||||
| THIRD QUARTER | |||||||||
| % Change | |||||||||
| 2021 | 2020 | Reported | Operational (1) | Currency | |||||
| MEDICAL DEVICES SEGMENT (2) (Continued) | |||||||||
| SURGERY | |||||||||
| US | $ | 948 | 913 | 3.9 | 3.9 | — | % | ||
| Intl | 1,457 | 1,239 | 17.6 | 14.8 | 2.8 | ||||
| WW | 2,405 | 2,152 | 11.8 | 10.2 | 1.6 | ||||
| ADVANCED | |||||||||
| US | 440 | 421 | 4.6 | 4.6 | — | ||||
| Intl | 705 | 579 | 21.8 | 18.4 | 3.4 | ||||
| WW | 1,144 | 1,000 | 14.6 | 12.6 | 2.0 | ||||
| GENERAL | |||||||||
| US | 508 | 492 | 3.3 | 3.3 | — | ||||
| Intl | 752 | 660 | 13.9 | 11.7 | 2.2 | ||||
| WW | 1,261 | 1,152 | 9.4 | 8.1 | 1.3 | ||||
| VISION | |||||||||
| US | 475 | 473 | 0.6 | 0.6 | — | ||||
| Intl | 714 | 608 | 17.4 | 17.4 | 0.0 | ||||
| WW | 1,189 | 1,081 | 10.1 | 10.0 | 0.1 | ||||
| CONTACT LENSES / OTHER | |||||||||
| US | 359 | 375 | (4.3) | (4.3) | — | ||||
| Intl | 522 | 455 | 14.9 | 15.2 | (0.3) | ||||
| WW | 882 | 830 | 6.2 | 6.4 | (0.2) | ||||
| SURGICAL | |||||||||
| US | 117 | 98 | 19.6 | 19.6 | — | ||||
| Intl | 191 | 153 | 24.7 | 23.7 | 1.0 | ||||
| WW | 308 | 251 | 22.7 | 22.1 | 0.6 | ||||
| TOTAL MEDICAL DEVICES | |||||||||
| US | 3,117 | 3,092 | 0.8 | 0.8 | — | ||||
| Intl | 3,527 | 3,058 | 15.4 | 13.3 | 2.1 | ||||
| WW | $ | 6,644 | 6,150 | 8.0 | % | 7.0 | % | 1.0 | % |
| See footnotes at end of schedule | |||||||||
| Johnson & Johnson | |||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Segment Sales | |||||||||
| (Dollars in Millions) | |||||||||
| NINE MONTHS | |||||||||
| % Change | |||||||||
| 2021 | 2020 | Reported | Operational (1) | Currency | |||||
| CONSUMER HEALTH SEGMENT (2) | |||||||||
| OTC | |||||||||
| US | $ | 1,960 | 1,917 | 2.2 | % | 2.2 | % | — | % |
| Intl | 1,894 | 1,722 | 10.0 | 3.9 | 6.1 | ||||
| WW | 3,854 | 3,639 | 5.9 | 3.0 | 2.9 | ||||
| SKIN HEALTH / BEAUTY | |||||||||
| US | 1,862 | 1,767 | 5.4 | 5.4 | — | ||||
| Intl | 1,595 | 1,506 | 5.9 | 2.1 | 3.8 | ||||
| WW | 3,457 | 3,273 | 5.6 | 3.9 | 1.7 | ||||
| ORAL CARE | |||||||||
| US | 478 | 510 | (6.2) | (6.2) | — | ||||
| Intl | 762 | 694 | 9.9 | 5.9 | 4.0 | ||||
| WW | 1,240 | 1,204 | 3.0 | 0.8 | 2.2 | ||||
| BABY CARE | |||||||||
| US | 288 | 279 | 3.3 | 3.3 | — | ||||
| Intl | 879 | 831 | 5.8 | 4.6 | 1.2 | ||||
| WW | 1,167 | 1,110 | 5.2 | 4.3 | 0.9 | ||||
| WOMEN'S HEALTH | |||||||||
| US | 9 | 10 | (5.7) | (5.7) | — | ||||
| Intl | 675 | 654 | 3.1 | 2.3 | 0.8 | ||||
| WW | 684 | 664 | 3.0 | 2.1 | 0.9 | ||||
| WOUND CARE / OTHER | |||||||||
| US | 390 | 370 | 5.3 | 5.3 | — | ||||
| Intl | 186 | 175 | 5.8 | 0.0 | 5.8 | ||||
| WW | 575 | 545 | 5.4 | 3.6 | 1.8 | ||||
| TOTAL CONSUMER HEALTH | |||||||||
| US | 4,987 | 4,853 | 2.8 | 2.8 | — | ||||
| Intl | 5,991 | 5,582 | 7.3 | 3.5 | 3.8 | ||||
| WW | $ | 10,978 | 10,435 | 5.2 | % | 3.1 | % | 2.1 | % |
| See footnotes at end of schedule | |||||||||
| Johnson & Johnson | |||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Segment Sales | |||||||||
| (Dollars in Millions) | |||||||||
| NINE MONTHS | |||||||||
| % Change | |||||||||
| 2021 | 2020 | Reported | Operational (1) | Currency | |||||
| PHARMACEUTICAL SEGMENT (2) (3) | |||||||||
| IMMUNOLOGY | |||||||||
| US | $ | 7,932 | 7,330 | 8.2 | % | 8.2 | % | — | % |
| Intl | 4,464 | 3,619 | 23.3 | 17.6 | 5.7 | ||||
| WW | 12,395 | 10,950 | 13.2 | 11.3 | 1.9 | ||||
| REMICADE | |||||||||
| US | 1,508 | 1,852 | (18.6) | (18.6) | — | ||||
| US Exports (4) | 197 | 321 | (38.7) | (38.7) | — | ||||
| Intl | 721 | 673 | 7.1 | 1.4 | 5.7 | ||||
| WW | 2,426 | 2,846 | (14.8) | (16.1) | 1.3 | ||||
| SIMPONI / SIMPONI ARIA | |||||||||
| US | 840 | 840 | 0.0 | 0.0 | — | ||||
| Intl | 877 | 827 | 6.1 | 2.8 | 3.3 | ||||
| WW | 1,717 | 1,667 | 3.0 | 1.4 | 1.6 | ||||
| STELARA | |||||||||
| US | 4,396 | 3,668 | 19.9 | 19.9 | — | ||||
| Intl | 2,404 | 1,795 | 33.9 | 27.5 | 6.4 | ||||
| WW | 6,800 | 5,463 | 24.5 | 22.4 | 2.1 | ||||
| TREMFYA | |||||||||
| US | 975 | 650 | 50.1 | 50.1 | — | ||||
| Intl | 459 | 316 | 45.4 | 38.0 | 7.4 | ||||
| WW | 1,434 | 965 | 48.5 | 46.1 | 2.4 | ||||
| OTHER IMMUNOLOGY | |||||||||
| US | 15 | — | * | * | — | ||||
| Intl | 3 | 9 | (68.6) | (70.8) | 2.2 | ||||
| WW | 18 | 9 | 91.6 | 89.5 | 2.1 | ||||
| INFECTIOUS DISEASES | |||||||||
| US | 1,635 | 1,265 | 29.2 | 29.2 | — | ||||
| Intl | 1,788 | 1,397 | 28.0 | 23.2 | 4.8 | ||||
| WW | 3,424 | 2,662 | 28.6 | 26.1 | 2.5 | ||||
| COVID-19 VACCINE | |||||||||
| US | 421 | — | * | * | — | ||||
| Intl | 346 | — | * | * | — | ||||
| WW | 766 | — | * | * | — | ||||
| EDURANT / rilpivirine | |||||||||
| US | 31 | 33 | (4.8) | (4.8) | — | ||||
| Intl | 733 | 684 | 7.2 | 1.7 | 5.5 | ||||
| WW | 764 | 716 | 6.7 | 1.4 | 5.3 | ||||
| PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | |||||||||
| US | 1,128 | 1,154 | (2.2) | (2.2) | — | ||||
| Intl | 440 | 461 | (4.6) | (8.6) | 4.0 | ||||
| WW | 1,568 | 1,615 | (2.9) | (4.1) | 1.2 | ||||
| OTHER INFECTIOUS DISEASES | |||||||||
| US | 55 | 79 | (29.6) | (29.6) | — | ||||
| Intl | 270 | 252 | 6.9 | 2.6 | 4.3 | ||||
| WW | 325 | 331 | (1.8) | (5.0) | 3.2 | ||||
| See footnotes at end of schedule | |||||||||
| Johnson & Johnson | |||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | |
| Segment Sales | |||||||||
| (Dollars in Millions) | |||||||||
| NINE MONTHS | |||||||||
| % Change | |||||||||
| 2021 | 2020 | Reported | Operational (1) | Currency | |||||
| PHARMACEUTICAL SEGMENT (2) (3) (Continued) | |||||||||
| NOSCIENCE | |||||||||
| US | 2,448 | 2,285 | 7.2 | % | 7.2 | % | — | % | |
| Intl | 2,770 | 2,565 | 8.0 | 4.1 | 3.9 | ||||
| WW | 5,218 | 4,850 | 7.6 | 5.5 | 2.1 | ||||
| CONCERTA / methylphenidate | |||||||||
| US | 117 | 150 | (22.1) | (22.1) | — | ||||
| Intl | 372 | 319 | 16.4 | 11.6 | 4.8 | ||||
| WW | 489 | 469 | 4.1 | 0.8 | 3.3 | ||||
| INVEGA SUSTENNA / XEPLION / INVEGA | |||||||||
| TRINZA / TREVICTA | |||||||||
| US | 1,882 | 1,704 | 10.4 | 10.4 | — | ||||
| Intl | 1,111 | 983 | 13.0 | 7.6 | 5.4 | ||||
| WW | 2,994 | 2,688 | 11.4 | 9.4 | 2.0 | ||||
| RISPERDAL CONSTA | |||||||||
| US | 210 | 220 | (4.7) | (4.7) | — | ||||
| Intl | 242 | 254 | (5.1) | (8.3) | 3.2 | ||||
| WW | 452 | 475 | (4.9) | (6.6) | 1.7 | ||||
| OTHER NOSCIENCE | |||||||||
| US | 239 | 210 | 13.9 | 13.9 | — | ||||
| Intl | 1,045 | 1,008 | 3.7 | 1.5 | 2.2 | ||||
| WW | 1,284 | 1,218 | 5.5 | 3.6 | 1.9 | ||||
| ONCOLOGY | |||||||||
| US | 4,364 | 3,623 | 20.4 | 20.4 | — | ||||
| Intl | 6,406 | 5,310 | 20.6 | 15.3 | 5.3 | ||||
| WW | 10,770 | 8,933 | 20.6 | 17.4 | 3.2 | ||||
| DARZALEX | |||||||||
| US | 2,302 | 1,540 | 49.5 | 49.5 | — | ||||
| Intl | 2,076 | 1,397 | 48.6 | 42.2 | 6.4 | ||||
| WW | 4,378 | 2,937 | 49.1 | 46.0 | 3.1 | ||||
| ERLEADA | |||||||||
| US | 578 | 407 | 41.8 | 41.8 | — | ||||
| Intl | 329 | 112 | * | * | * | ||||
| WW | 907 | 519 | 74.7 | 72.2 | 2.5 | ||||
| IMBRUVICA | |||||||||
| US | 1,311 | 1,329 | (1.3) | (1.3) | — | ||||
| Intl | 1,996 | 1,682 | 18.7 | 13.1 | 5.6 | ||||
| WW | 3,307 | 3,011 | 9.9 | 6.7 | 3.2 | ||||
| ZYTIGA / abiraterone acetate | |||||||||
| US | 96 | 284 | (66.2) | (66.2) | — | ||||
| Intl | 1,653 | 1,564 | 5.7 | 0.9 | 4.8 | ||||
| WW | 1,749 | 1,848 | (5.4) | (9.4) | 4.0 | ||||
| OTHER ONCOLOGY | |||||||||
| US | 76 | 63 | 21.0 | 21.0 | — | ||||
| Intl | 352 | 556 | (36.6) | (38.5) | 1.9 | ||||
| WW | 428 | 619 | (30.7) | (32.4) | 1.7 | ||||
| See footnotes at end of schedule |
All values are in Euros.
| Johnson & Johnson | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Segment Sales | |||||||||
| (Dollars in Millions) | |||||||||
| NINE MONTHS | |||||||||
| % Change | |||||||||
| 2021 | 2020 | Reported | Operational (1) | Currency | |||||
| PHARMACEUTICAL SEGMENT (2) (3) (Continued) | |||||||||
| PULMONARY HYPERTENSION | |||||||||
| US | $ | 1,778 | 1,541 | 15.4 | % | 15.4 | % | — | % |
| Intl | 821 | 742 | 10.7 | 7.3 | 3.4 | ||||
| WW | 2,599 | 2,283 | 13.9 | 12.7 | 1.2 | ||||
| OPSUMIT | |||||||||
| US | 861 | 729 | 18.2 | 18.2 | — | ||||
| Intl | 510 | 458 | 11.3 | 7.7 | 3.6 | ||||
| WW | 1,371 | 1,187 | 15.5 | 14.1 | 1.4 | ||||
| UPTRAVI | |||||||||
| US | 792 | 692 | 14.6 | 14.6 | — | ||||
| Intl | 135 | 100 | 34.6 | 27.9 | 6.7 | ||||
| WW | 927 | 792 | 17.1 | 16.2 | 0.9 | ||||
| OTHER PULMONARY HYPERTENSION | |||||||||
| US | 125 | 121 | 2.8 | 2.8 | — | ||||
| Intl | 176 | 183 | (3.7) | (5.0) | 1.3 | ||||
| WW | 301 | 304 | (1.1) | (1.9) | 0.8 | ||||
| CARDIOVASCULAR / METABOLISM / OTHER | |||||||||
| US | 2,379 | 2,574 | (7.6) | (7.6) | — | ||||
| Intl | 1,007 | 1,052 | (4.2) | (9.3) | 5.1 | ||||
| WW | 3,386 | 3,625 | (6.6) | (8.1) | 1.5 | ||||
| XARELTO | |||||||||
| US | 1,794 | 1,716 | 4.5 | 4.5 | — | ||||
| Intl | — | — | — | — | — | ||||
| WW | 1,794 | 1,716 | 4.5 | 4.5 | — | ||||
| INVOKANA / INVOKAMET | |||||||||
| US | 249 | 405 | (38.4) | (38.4) | — | ||||
| Intl | 194 | 173 | 11.9 | 5.8 | 6.1 | ||||
| WW | 443 | 578 | (23.4) | (25.2) | 1.8 | ||||
| PROCRIT / EPREX | |||||||||
| US | 168 | 215 | (21.7) | (21.7) | — | ||||
| Intl | 198 | 208 | (4.7) | (9.7) | 5.0 | ||||
| WW | 366 | 423 | (13.4) | (15.8) | 2.4 | ||||
| OTHER | |||||||||
| US | 168 | 238 | (29.3) | (29.3) | — | ||||
| Intl | 615 | 670 | (8.3) | (13.1) | 4.8 | ||||
| WW | 783 | 908 | (13.8) | (17.3) | 3.5 | ||||
| TOTAL PHARMACEUTICAL | |||||||||
| US | 20,536 | 18,619 | 10.3 | 10.3 | — | ||||
| Intl | 17,256 | 14,685 | 17.5 | 12.5 | 5.0 | ||||
| WW | $ | 37,792 | 33,304 | 13.5 | % | 11.3 | % | 2.2 | % |
| See footnotes at end of schedule | |||||||||
| Johnson & Johnson | |||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Segment Sales | |||||||||
| (Dollars in Millions) | |||||||||
| NINE MONTHS | |||||||||
| % Change | |||||||||
| 2021 | 2020 | Reported | Operational (1) | Currency | |||||
| MEDICAL DEVICES SEGMENT (2) | |||||||||
| INTERVENTIONAL SOLUTIONS | |||||||||
| US | $ | 1,353 | 1,019 | 32.7 | % | 32.7 | % | — | % |
| Intl | 1,599 | 1,134 | 41.1 | 34.3 | 6.8 | ||||
| WW | 2,952 | 2,153 | 37.1 | 33.6 | 3.5 | ||||
| ORTHOPAEDICS | |||||||||
| US | 3,821 | 3,427 | 11.5 | 11.5 | — | ||||
| Intl | 2,611 | 2,145 | 21.7 | 15.4 | 6.3 | ||||
| WW | 6,433 | 5,572 | 15.4 | 13.0 | 2.4 | ||||
| HIPS | |||||||||
| US | 654 | 564 | 15.9 | 15.9 | — | ||||
| Intl | 451 | 344 | 31.3 | 24.1 | 7.2 | ||||
| WW | 1,105 | 908 | 21.8 | 19.0 | 2.8 | ||||
| KNEES | |||||||||
| US | 579 | 527 | 10.0 | 10.0 | — | ||||
| Intl | 403 | 298 | 35.4 | 28.2 | 7.2 | ||||
| WW | 983 | 825 | 19.2 | 16.6 | 2.6 | ||||
| TRAUMA | |||||||||
| US | 1,352 | 1,194 | 13.3 | 13.3 | — | ||||
| Intl | 805 | 698 | 15.2 | 9.5 | 5.7 | ||||
| WW | 2,157 | 1,892 | 14.0 | 11.9 | 2.1 | ||||
| SPINE, SPORTS & OTHER | |||||||||
| US | 1,236 | 1,142 | 8.2 | 8.2 | — | ||||
| Intl | 952 | 805 | 18.2 | 12.0 | 6.2 | ||||
| WW | 2,187 | 1,947 | 12.3 | 9.7 | 2.6 | ||||
| See footnotes at end of schedule | |||||||||
| Johnson & Johnson | |||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Segment Sales | |||||||||
| (Dollars in Millions) | |||||||||
| NINE MONTHS | |||||||||
| % Change | |||||||||
| 2021 | 2020 | Reported | Operational (1) | Currency | |||||
| MEDICAL DEVICES SEGMENT (2) (Continued) | |||||||||
| SURGERY | |||||||||
| US | $ | 2,881 | 2,247 | 28.2 | % | 28.2 | % | — | % |
| Intl | 4,418 | 3,556 | 24.2 | 18.4 | 5.8 | ||||
| WW | 7,299 | 5,803 | 25.8 | 22.2 | 3.6 | ||||
| ADVANCED | |||||||||
| US | 1,304 | 1,079 | 20.9 | 20.9 | — | ||||
| Intl | 2,126 | 1,644 | 29.3 | 23.1 | 6.2 | ||||
| WW | 3,430 | 2,723 | 26.0 | 22.2 | 3.8 | ||||
| GENERAL | |||||||||
| US | 1,577 | 1,168 | 35.0 | 35.0 | — | ||||
| Intl | 2,292 | 1,912 | 19.9 | 14.5 | 5.4 | ||||
| WW | 3,869 | 3,080 | 25.6 | 22.3 | 3.3 | ||||
| VISION | |||||||||
| US | 1,414 | 1,160 | 21.9 | 21.9 | — | ||||
| Intl | 2,103 | 1,683 | 25.0 | 22.0 | 3.0 | ||||
| WW | 3,517 | 2,843 | 23.7 | 22.0 | 1.7 | ||||
| CONTACT LENSES / OTHER | |||||||||
| US | 1,082 | 924 | 17.0 | 17.0 | — | ||||
| Intl | 1,525 | 1,274 | 19.8 | 17.3 | 2.5 | ||||
| WW | 2,607 | 2,198 | 18.6 | 17.2 | 1.4 | ||||
| SURGICAL | |||||||||
| US | 333 | 236 | 41.1 | 41.1 | — | ||||
| Intl | 577 | 409 | 41.1 | 36.7 | 4.4 | ||||
| WW | 910 | 645 | 41.1 | 38.3 | 2.8 | ||||
| TOTAL MEDICAL DEVICES | |||||||||
| US | 9,470 | 7,852 | 20.6 | 20.6 | — | ||||
| Intl | 10,731 | 8,518 | 26.0 | 20.5 | 5.5 | ||||
| WW | $ | 20,201 | 16,370 | 23.4 | % | 20.5 | % | 2.9 | % |
| Note: Column and rows within tables may not add due to rounding. Percentages have been calculated using actual, non- | |||||||||
| rounded figures and, therefore, may not recalculate precisely. | |||||||||
| * Percentage greater than 100% or not meaningful | |||||||||
| (1) Operational growth excludes the effect of translational currency | |||||||||
| (2) Unaudited | |||||||||
| (3) Certain prior year amounts have been reclassified to conform to current year product disclosures | |||||||||
| (4) Reported as U.S. sales |
Document
Exhibit 99.3
MEDIA CONTACT:
Kimberly Montagnino
Phone: 732-524-1090
media-relations@its.jnj.com
INVESTOR CONTACT:
Lisa Romanko
lromank3@its.jnj.com
Johnson & Johnson Takes Steps to Equitably Resolve All Current and Future Talc Claims
New Subsidiary LTL Management LLC Files for Voluntary Chapter 11
Among Other Measures, $2 Billion Trust Will Be Established to Facilitate an Efficient Resolution of Claims
NEW BRUNSWICK, N.J., October 14, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that LTL Management LLC (LTL), a newly created and separate subsidiary of Johnson & Johnson, that was established to hold and manage claims in the cosmetic talc litigation, has filed for voluntary Chapter 11 bankruptcy protection. This filing is intended to resolve all claims related to cosmetic talc in a manner that is equitable to all parties, including any current and future claimants. Johnson & Johnson and its other affiliates did not file for bankruptcy protection and will continue to operate their businesses as usual.
“We are taking these actions to bring certainty to all parties involved in the cosmetic talc cases,” said Michael Ullmann, Executive Vice President, General Counsel of Johnson & Johnson. “While we continue to stand firmly behind the safety of our cosmetic talc products, we believe resolving this matter as quickly and efficiently as possible is in the best interests of the Company and all stakeholders.”
To demonstrate its commitment to resolving the cosmetic talc cases and remove any financial objections to the process, Johnson & Johnson has agreed to provide funding to LTL for the payment of amounts the Bankruptcy Court determines are owed by LTL and will also establish a $2 billion trust in furtherance of this purpose. In addition, LTL has been allocated certain royalty revenue streams with a present value of over $350 million to further contribute to potential costs.
John Kim, Chief Legal Officer of LTL, said, “With the financial backing of Johnson & Johnson, coupled with a dedicated trust and significant financial resources supporting LTL, we are confident all parties will be treated equitably during this process.”
These actions are not a concession of liability but rather a means to achieve an equitable and efficient resolution of the claims raised in the cosmetic talc litigation. The Company has won the majority of cosmetic talc-related jury trials that have been litigated to date and continues to believe that none of the talc-related claims against the Company have merit. The claims are premised on the allegation that cosmetic talc causes ovarian cancer and mesothelioma, a position that has been rejected by independent experts, as well as governmental and regulatory bodies, for decades. More than 40 years of studies by medical experts around the world continue to support the safety of cosmetic talc.
The determination of an appropriate amount to resolve all current and future claims will be decided by the Bankruptcy Court in the Chapter 11 proceedings. This established process will allow for a more efficient and consistent resolution for all parties. While LTL pursues this equitable resolution, all cosmetic talc cases will be stayed pending the outcome of the proceedings.
Johnson & Johnson remains focused on its mission to improve the trajectory of health for humanity and committed to developing lifesaving therapies and innovative solutions that help people live their healthiest lives. LTL’s Chapter 11 case was filed in the U.S. Bankruptcy Court for the Western District of North Carolina. Additional information is available on www.FactsAboutTalc.com and www.LTLManagementInformation.com. Court filings and information about LTL’s Chapter 11 case are available on a separate website administered by its claims agent, Epiq, at https://
dm.epiq11.com/LTL; by calling Epiq representatives at (855) 675-3078 from the U.S. or (503) 520-4497 from international locations; or by emailing Epiq at LTLinfo@epiqglobal.com.
About Johnson & Johnson At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity. Learn more at www.jnj.com. Follow us at @JNJNews.
Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding the voluntary Chapter 11 bankruptcy filing by LTL Management LLC, a newly created and separate subsidiary of Johnson & Johnson. The reader is cautioned not to rely on these forward-looking statements. The information contained in this press release is for informational purposes only and should not be construed as a commitment by the Company to engage in any specific strategy or course of action. Due to the inherent uncertainty of litigation, the Company cannot predict the timing, ultimate outcome or financial impact of this matter, or any other ongoing or future litigation. The forward-looking statements in this press release are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of LTL Management LLC, Johnson & Johnson Consumer Inc. and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: significant adverse litigation or government action, including related to product liability claims; economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2021, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” in the company’s most recently filed Quarterly Report on Form 10-Q and in the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. None of LTL Management LLC, Johnson & Johnson Consumer Inc. nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments. The Company expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.